Loading…
Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments. It offers upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and oral electrolyte beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. The company also offers healthy lifestyle products, such as smoking cessation and well-being products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women's health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; and other miscellaneous self-care products. It sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, and Compeed brands. The company also offers contract manufacturing services. It sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $4.3B | $-798M | $-1.4B | $145M | -48.6% | -2.8% | 729.7% |
| 2024 | $4.4B | $433M | $-172M | $245M | -4.0% | -6.1% | 1252.8% |
| 2023 | $4.7B | $525M | $-13M | $304M | -0.3% | 4.6% | -91.0% |
| 2022 | $4.5B | $356M | $-141M | $211M | -2.9% | - | - |
| 2021 | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 4,451.60 | 4,655.60 | 4,373.40 | 4,253.10 |
| Operating Revenue | - | 4,451.60 | 4,655.60 | 4,373.40 | 4,253.10 |
| Cost Of Revenue | - | 2,996.20 | 2,975.20 | 2,830.70 | 2,758.60 |
| Gross Profit | - | 1,455.40 | 1,680.40 | 1,542.70 | 1,494.50 |
| Operating Expense | - | 1,334 | 1,396.30 | 1,230.80 | 1,181.70 |
| Research And Development | - | 123.10 | 122.50 | 112.20 | 95.40 |
| Selling General And Administration | - | 1,210.10 | 1,274.60 | 1,112.60 | 1,055.80 |
| Total Expenses | - | 4,330.20 | 4,371.50 | 4,061.50 | 3,940.30 |
| Operating Income | - | 121.40 | 284.10 | 311.90 | 312.80 |
| Total Operating Income As Reported | - | 78.90 | 151.90 | 112.90 | -1,122.20 |
| EBITDA | - | 355.50 | 525 | 433 | -797.90 |
| Normalized EBITDA | - | 406.90 | 654 | 638.70 | 637.10 |
| EBIT | - | 16.90 | 165.50 | 107.10 | -1,135.40 |
| Interest Expense | - | 156 | 173.80 | 187.80 | 162.50 |
| Net Interest Income | - | -156 | -173.80 | -187.80 | -162.50 |
| Other Non Operating Income Expenses | - | -53.10 | 10.40 | 0.90 | -13.20 |
| Other Income Expense | - | -104.50 | -118.60 | -204.80 | -1,448.20 |
| Interest Expense Non Operating | - | 156 | 173.80 | 187.80 | 162.50 |
| Net Non Operating Interest Income Expense | - | -156 | -173.80 | -187.80 | -162.50 |
| Pretax Income | - | -139.10 | -8.30 | -80.70 | -1,297.90 |
| Tax Provision | - | -8.20 | -3.90 | 80 | 104.40 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | -3.03 | -27.09 | -43.20 | -301.35 |
| Net Income Continuous Operations | - | -130.90 | -4.40 | -160.70 | -1,402.30 |
| Net Income From Continuing And Discontinued Operation | - | -140.60 | -12.70 | -171.80 | -1,425.40 |
| Net Income From Continuing Operation Net Minority Interest | - | -130.90 | -4.40 | -160.70 | -1,402.30 |
| Net Income | - | -140.60 | -12.70 | -171.80 | -1,425.40 |
| Net Income Common Stockholders | - | -140.60 | -12.70 | -171.80 | -1,425.40 |
| Net Income Including Noncontrolling Interests | - | -140.60 | -12.70 | -171.80 | -1,425.40 |
| Normalized Income | - | -82.53 | 97.51 | 1.80 | -268.65 |
| Diluted NI Availto Com Stockholders | - | -140.60 | -12.70 | -171.80 | -1,425.40 |
| Basic Average Shares | - | 134.50 | 135.30 | 137.40 | 138.50 |
| Diluted Average Shares | - | 134.50 | 135.30 | 137.40 | 138.50 |
| Reconciled Depreciation | - | 338.60 | 359.50 | 325.90 | 337.50 |
| Reconciled Cost Of Revenue | - | 2,996.20 | 2,975.20 | 2,830.70 | 2,758.60 |
| Total Unusual Items | - | -51.40 | -129 | -205.70 | -1,435 |
| Total Unusual Items Excluding Goodwill | - | -51.40 | -129 | -205.70 | -1,435 |
| Net Income Discontinuous Operations | - | -9.70 | -8.30 | -11.10 | -23.10 |
| Special Income Charges | - | -51.40 | -129 | -205.70 | -1,435 |
| Other Special Charges | - | 8.90 | -3.20 | 6.70 | - |
| Write Off | - | 0 | 90 | 88.90 | 1,363.10 |
| Restructuring And Mergern Acquisition | - | 42.50 | 42.20 | 110.10 | 71.90 |
| General And Administrative Expense | - | 512.30 | 522.30 | 468 | 435.90 |
| Other Gand A | - | 512.30 | 522.30 | 468 | 435.90 |
| Total Other Finance Cost | 125 | - | - | - | - |
| Other Operating Expenses | - | 0.80 | -0.80 | 6 | 30.50 |
| Selling And Marketing Expense | - | 697.80 | 752.30 | 644.60 | 619.90 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Perrigo Company plcthis co. | PRGO | $1.5B | -1.04 | 0.50 | -48.6% | -5.75 |
| PROCEPT BioRobotics Corporation | PRCT | $1.5B | -16.08 | 4.20 | -26.1% | -15.56 |
| AnaptysBio, Inc. | ANAB | $1.5B | - | 40.41 | -35.6% | 17.42 |
| STAAR Surgical Company | STAA | $1.5B | -18.48 | 4.32 | -23.4% | -36.86 |
| NeoGenomics, Inc. | NEO | $1.5B | -13.63 |
| - |
| - |
| - |
| - |
| - |
| 1.76 |
| -12.9% |
| -44.52 |
| MBX Biosciences, Inc. | MBX | $1.5B | -16.92 | 3.98 | -23.6% | -14.28 |
| Monte Rosa Therapeutics, Inc. | GLUE | $1.5B | -37.97 | 6.29 | -16.6% | -30.01 |
| Aveanna Healthcare Holdings Inc. | AVAH | $1.4B | 6.42 | 7.40 | 115.3% | 10.26 |
| Septerna, Inc. | SEPN | $1.4B | -28.93 | 3.70 | -12.8% | -16.63 |
| Peer Median | - | -16.92 | 4.26 | -20.0% | -16.09 | |